Latest Ratings for LLY
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Morgan Stanley | Maintains | Overweight | |
| Feb 2022 | Mizuho | Maintains | Buy | |
| Jan 2022 | Morgan Stanley | Maintains | Overweight |
Assessing Eli Lilly: Insights From 7 Financial Analysts
Where Today's News Shapes Tomorrow
